Aimovig pregnancy safety study for migraine
Part of Brain & nervous system clinical trials.
This study tracks the health of pregnant women with migraine who take Aimovig. It helps doctors understand if the medicine is safe to use during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are currently pregnant
- You do not yet know the outcome of your pregnancy (such as whether the baby is healthy)
- You have been diagnosed with migraine by a doctor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study looks at health outcomes for moms, babies, and infants after rimegepant is used during pregnancy for migraine. It may help doctors understand potential risks or reassuring safety information for future pregnancies.
This is an observational study (no treatment is assigned) that tracks side effects and pregnancy outcomes in people taking Ubrelvy or Qulipta for migraine during pregnancy. It may help doctors better understand how these medicines affect mothers and babies.
This study tracks how well new migraine medications (like Aimovig, Emgality, Ajovy, Vyepti, Qulipta, and Nurtec) work in everyday use. It may help you and your doctor understand if these treatments are a good option for your migraines.
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
This study tests a medicine called rimegepant to see if it helps prevent migraines. If you have migraine at least 4 days per month, this might be for you.
This study tests if atogepant, a daily pill, can prevent migraines in adults. It is for people whose doctor has already decided to prescribe atogepant for migraine prevention.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.